Executive brief
Assess AI readiness before pilots become risk
An AI readiness assessment helps life sciences organizations understand whether they are prepared to adopt, govern, validate, and scale AI in regulated environments. It is the practical first step between AI ambition and controlled execution.
Many teams already have AI experiments underway. Business users are testing generative AI, software vendors are embedding AI features into enterprise platforms, and executives are asking where AI can create value. The risk is that adoption often moves faster than governance, data controls, validation strategy, and quality oversight.
USDM's assessment gives leaders a current-state baseline across AI maturity, data readiness, governance, validation, vendor exposure, and use-case priority. The output is a roadmap that shows what can move now, what needs control first, and where the organization should focus investment.
AI readiness assessment focus areas
- AI maturity assessment: where the organization sits today across strategy, ownership, controls, and execution.
- Life sciences AI readiness: how prepared regulated teams are to use AI in Quality, Regulatory, Clinical, Manufacturing, IT, and commercial workflows.
- Data and validation readiness: whether data classification, lineage, intended use, testing, and monitoring can support trusted AI outputs.
- Use-case prioritization: which AI opportunities offer the strongest mix of value, feasibility, and acceptable GxP risk.
Readiness map
From AI interest to controlled execution.
The assessment connects business value, GxP risk, data readiness, governance, and validation strategy before teams scale AI into regulated workflows.
- 1. BaselineCurrent AI maturity, active pilots, data sources, and vendor exposure.
- 2. ClassifyUse-case value, GxP impact, human oversight, and evidence needs.
- 3. PrioritizeRoadmap decisions by feasibility, compliance risk, and business value.
- 4. GovernControls, validation expectations, monitoring, and accountable ownership.
What an AI readiness assessment evaluates
A meaningful assessment is not a generic technology survey. In life sciences, AI readiness must connect business value with AI governance, data integrity, validation controls, cybersecurity, and operating-model accountability.
USDM typically evaluates readiness across several domains:
- Strategy and sponsorship: whether leaders have defined business objectives, risk appetite, ownership, and funding for AI adoption.
- AI system inventory: where AI is already active, including embedded vendor AI, shadow AI, copilots, analytics tools, and regulated workflow use cases.
- Data foundation: whether data is classified, governed, traceable, accessible, and fit for AI-enabled workflows.
- Governance model: whether policies, SOPs, risk classification, human oversight, escalation paths, and evidence requirements are defined.
- Validation and lifecycle controls: how the organization will define intended use, test AI-enabled functionality, monitor performance, and manage change over time.
- Third-party and platform AI risk: how vendors, partner platforms, model providers, and embedded AI features are assessed and monitored.
- Use-case roadmap: which AI opportunities should move first based on value, feasibility, data readiness, and compliance exposure.
Why life sciences AI readiness is different
Generic AI readiness frameworks usually focus on infrastructure, skills, and data maturity. Those matter, but they are not enough for regulated organizations. A life sciences AI readiness assessment also has to account for GxP applicability, intended use, evidence, audit trails, human review, validation lifecycle management, and vendor accountability.
That is especially important when AI supports quality decisions, regulatory content, clinical operations, manufacturing oversight, complaint handling, deviation analysis, or validated system workflows. These uses require more than productivity guidance. They require controlled processes that can be defended under regulatory scrutiny.
For teams early in the journey, USDM's AI Readiness Assessment for Life Sciences article explains the broader operating model. The assessment page turns that thinking into a service path: baseline the current state, classify risk, prioritize use cases, and build a roadmap.
How the assessment turns AI interest into a roadmap
The most useful AI maturity assessment does not simply score the organization. It helps leadership decide what to do next.
Typical outputs include:
- AI maturity baseline and prioritized gap analysis.
- Current and emerging AI use-case inventory.
- Data readiness and data classification findings.
- Governance and validation control recommendations.
- AI vendor and embedded platform risk findings.
- Use-case prioritization matrix for value, feasibility, and risk.
- 90-day action plan for moving from assessment to controlled execution.
Start with the use cases worth winning
AI readiness becomes practical when the assessment connects governance to real work. USDM helps teams evaluate use cases across Quality, Regulatory, Clinical, Manufacturing, IT, Commercial, and Medical functions, then decide which should move first.
The best first use cases usually have clear business value, available data, manageable validation risk, defined human oversight, and a visible path to adoption. Higher-risk use cases may still be valuable, but they should move only after the governance and evidence model is ready.
For examples of where AI can create measurable value, see USDM's AI in Life Sciences use-case dossier and the AI Governance for Life Sciences enterprise framework.
Talk to USDM about AI readiness
If your organization is evaluating AI but needs a clearer view of risk, readiness, and next steps, USDM can help. We bring life sciences compliance, validation, data, and AI governance expertise together so the assessment produces decisions your teams can actually execute.
Contact USDM to discuss an AI readiness assessment for your organization.
